Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+27.78% | +53.33% |
07-16 | SciSparc Receives Nasdaq Noncompliance Notice | MT |
07-16 | SciSparc Seeks Patent for Obesity Drug Ingredient's Composition | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 14.17 | 5.09 | 2.556 |
Enterprise Value (EV) 1 | 7.362 | 1.543 | -2.444 |
P/E ratio | -2.2 x | -1.33 x | -0.34 x |
Yield | - | - | - |
Capitalization / Revenue | - | 3,779,071 x | 887,821 x |
EV / Revenue | - | 1,145,812 x | -848,893 x |
EV / EBITDA | -1.28 x | -0.19 x | 0.46 x |
EV / FCF | -1.43 x | -0.38 x | 0.41 x |
FCF Yield | -69.9% | -266% | 242% |
Price to Book | 2.37 x | 0.8 x | 0.45 x |
Nbr of stocks (in thousands) | 87.5 | 259 | 524 |
Reference price 2 | 162.0 | 19.64 | 4.880 |
Announcement Date | 28/04/22 | 01/05/23 | 01/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | 1.347 | 2.879 |
EBITDA 1 | -9.142 | -3.986 | -2.387 | -5.755 | -8.1 | -5.282 |
EBIT 1 | -9.289 | -4.108 | -2.551 | -5.768 | -8.287 | -5.773 |
Operating Margin | - | - | - | - | -615.22% | -200.52% |
Earnings before Tax (EBT) 1 | -9.009 | -4.479 | -3.535 | -5.789 | -2.578 | -5.861 |
Net income 1 | -8.523 | -4.794 | -3.482 | -5.789 | -2.592 | -5.122 |
Net margin | - | - | - | - | -192.43% | -177.91% |
EPS | - | - | - | -73.58 | -14.82 | -14.43 |
Free Cash Flow 1 | -3.632 | -3.688 | -1.91 | -5.145 | -4.105 | -5.923 |
FCF margin | - | - | - | - | -304.78% | -205.72% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 15/05/19 | 15/06/20 | 30/03/21 | 28/04/22 | 01/05/23 | 01/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 0.34 | 0.71 | 1.76 | 6.81 | 3.55 | 5 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -3.63 | -3.69 | -1.91 | -5.15 | -4.11 | -5.92 |
ROE (net income / shareholders' equity) | -211% | -9,844% | -490% | -121% | -35.5% | -73.4% |
ROA (Net income/ Total Assets) | -82.2% | -89.9% | -85.8% | -57.8% | -50.5% | -33.1% |
Assets 1 | 10.37 | 5.335 | 4.057 | 10.02 | 5.135 | 15.46 |
Book Value Per Share | - | - | 35.90 | 68.50 | 24.70 | 10.80 |
Cash Flow per Share | - | - | 48.80 | 57.80 | 13.70 | 2.940 |
Capex 1 | 0.02 | 0 | - | 0.04 | 0.01 | - |
Capex / Sales | - | - | - | - | 0.59% | - |
Announcement Date | 15/05/19 | 15/06/20 | 30/03/21 | 28/04/22 | 01/05/23 | 01/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.40% | 45.35B | |
+38.38% | 24.34B | |
+26.31% | 16.51B | |
+21.19% | 14.6B | |
+71.91% | 14.27B | |
-0.05% | 6.79B | |
-11.63% | 6.57B | |
+15.08% | 5.76B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- SPRC Stock
- TRPXY Stock
- Financials Therapix Biosciences Ltd.